Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
EHC · NYSE · Health Care Facilities
Encompass Health (EHC) · oqro.io/stocks/EHC · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$132.28−2.65 (−1.96%)
Close of Nov 19, 2026, vs Nov 18 · end-of-day
No open-market purchase by an insider of Encompass Health was filed in the last 90 days. The latest on record was on May 3, 2024.
Since 2007, Encompass Health insiders reported 125 open-market purchases and 77 sales on Forms 4 and 5, with purchases in 14 different years, most recently 2024.
In the last 90 days, 2 insiders of Encompass Health (EHC) reported 2 open-market sales worth $1.22M in total on SEC Form 4. The largest seller by value was Andrew L Price, with $630K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 3 trades in Encompass Health (EHC) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. Lisa C. McClain (MI09).
Encompass Health's next results are expected on Feb 3, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+18.2% (+$20.36) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
Adjusted close went from $111.92 on Nov 19, 2025 to $132.28 on Nov 19, 2026 (+18.2%). Disclosed in this range: 18 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 41 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Facilities company based in Birmingham, Alabama.
Last 12 months
+18.2%
Market value
$13B
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 3.61M shares sold short (3.7% of shares outstanding), +9.1% vs the previous count, 2.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$5.94B
+10.5% vs the year before
Net income, fiscal 2025
$566M
As reported in the annual filing
Shares outstanding
98.1M
As of Oct 22, 2026
In fiscal 2025 the company spent $158M buying back its own shares and $71.1M on dividends. Cash actually paid, from its cash-flow statement.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Insider selling
Traded Aug 31 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade +10.0% · S&P 500 −6.7% · to Nov 19
Encompass Health's Chief Accounting Officer sold $630K of Encompass Health shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Aug 31 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade +10.0% · S&P 500 −6.7% · to Nov 19
Encompass Health's Gen Counsel & Secretary sold $588K of Encompass Health shares. The filing does not indicate a pre-arranged trading plan.
Fund moves
23 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
23 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
$1.61B
+8.9% vs the same quarter a year earlier
Free cash flow, last 12 months
$457M
This quarter $128M, a year earlier $83.7M
Net debt
$2.48B
Debt $2.55B, cash $76.2M, at Sep 30, 2026
Net income, last 12 months
$644M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 28, 2026.
Revenue and earnings history, 18 fiscal yearsEarnings dates and the stock's moves
Against the S&P 500 over the year
Since Nov 18, 2025, EHC is up 17.4% and the index fund is up 8.5%: 9 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much EHC moves
Beta 0.0 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 250 trading days (1 = in step with it).
No Schedule 13D or 13G filing on EHC over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Insiders of Encompass Health reported 125 open-market purchases and 77 sales since 2007; purchases in 14 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $47.8M18×18 trades |
| 2025 | — | $21.7M9×9 trades |
| 2024 | $167K1×1 trade | $6.87M5×5 trades |
| 2023 | — | $4.18M4×4 trades |
| 2022 | $167K2×2 trades | $1.09M1×1 trade |
| 2021 | $20K1×1 trade | $699K1×1 trade |
| 2020 | $9.97M9×9 trades | $4.18M6×6 trades |
| 2019 | $93K2×2 trades | $4.28M2×2 trades |
| 2018 | — | $7.34M7×7 trades |
| 2017 | $46K1×1 trade | $1.94M2×2 trades |
| 2016 | $531K4×4 trades | $1.87M4×4 trades |
| 2015 | $80K3×3 trades | $532K2×2 trades |
| 2014 | — | $5.89M10×10 trades |
| 2013 | $28K1×1 trade | $450K2×2 trades |
| 2012 | $313K4×4 trades | $812K4×4 trades |
| 2010 | $36K1×1 trade | — |
| 2009 | $75K1×1 trade | — |
| 2008 | $1.29M69×69 trades | — |
| 2007 | $2.88M26×26 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
1 certified in FY2026 Q3, vs 2 a year earlier. 1 position in total, median offered wage $170K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Latest annual report filed Feb 26, 2026, compared with the one filed Feb 28, 2025. Read the filing
All 31 risk factor headings match the year before, give or take wording.
We provide services in the highly regulated healthcare industry. Furthermore, operating inpatient rehabilitation hospitals requires significant staffing and involves intensive therapy for individuals suffering from significant physical or cognitive disabilities or injuries. In the ordinary course of our business, we are subject to regulatory and other governmental audits and investigations and are party to various legal actions, proceedings, and claims, including wage and hour, employment and personal injury claims, some of which seek to be certified as class or collective actions.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 3, 2026. Quarterly reports are not audited. Read the filing
+13% on the same quarter a year earlier ($946M)
+2.9% on the same quarter a year earlier ($246M)
+5.3% on the same quarter a year earlier ($165M)
−0.8% on the same quarter a year earlier ($50M)
−21% on the same quarter a year earlier ($47.9M)
+21% on the same quarter a year earlier ($9.8M)
−3.5% on the same quarter a year earlier ($8.5M)
+63% on the same quarter a year earlier ($4.9M)
The company also reports Inpatient ($1.57B), Other ($40.4M), which group lines above and are not added again.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 26, 2026. Read the filing
+10% on the year before ($5.23B)
+25% on the year before ($143M)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 11,000 words.
We are the nation’s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals. We provide specialized rehabilitative treatment, using advanced technology and intensive therapy, on an inpatient basis for patients recovering from a major injury or illness and seeking to regain functional ability, independence and quality of life. We operate hospitals in 39 states and Puerto Rico, with concentrations in Florida and Texas. As of December 31, 2025, we operated 173 inpatient rehabilitation hospitals. For additional information about our business, see Item 1, Business, and Item 1A, Risk Factors, of this report. During 2025, Net operating revenues increased 10.5% over 2024 due primarily to volume growth and increased pricing.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026 and Form 10-Q filed Nov 3, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Company reports, price and press
Who holds it
Things to keep in mind
And 20 more headings in the filing.
Fails to deliver: 45K shares (about $5.57M) were not delivered on time for settlement on Oct 7, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 42.4% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (30.6% on ATS, 11.8% with other brokers), close to its 26-week average of 43.2%. Weeks of Oct 5 to Oct 30, 2026.
Largest ATS: INTELLIGENT CROSS LLC (13.9%), UBS ATS (13.6%), SIGMA X2 (12.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Last results
Oct 28, 2026
Within the 30 days after it, until Nov 27, 2026
Next results, expected
Feb 3, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
33%
5 of 15 insider purchases since 2018 came within 30 days after a results announcement
From Encompass Health's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Encompass Health's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.